AI Article Synopsis
- The study aimed to assess serum levels of relaxin (RLX) in patients with systemic sclerosis (SSc), known for its antifibrotic properties.
- The pilot study involved 50 SSc patients and 50 healthy controls, measuring RLX using an ELISA and conducting statistical analysis with Student's t test.
- Results showed significantly higher RLX levels in SSc patients compared to controls, with notable increases in both male and female patients, indicating RLX may provide a protective response against fibrosis in SSc.
Article Abstract
Objective: To evaluate serum levels of relaxin (RLX), a hormone with acknowledged antifibrotic activity, in patients with systemic sclerosis (SSc).
Methods: We performed a pilot study of 50 outpatients with SSc and 50 healthy subjects. Serum RLX was measured using the relaxin ELISA. Statistical analysis was performed using Student's t test.
Results: Serum RLX appeared to be significantly higher (p < 0.001) in patients with SSc compared to controls. RLX appeared significantly increased (p < 0.001) in male patients compared to male controls, and in female patients compared to female controls. RLX was significantly higher (p < 0.001) in female patients and female controls compared to male patients and male controls.
Conclusion: In patients with SSc, the increased level of RLX represents a defensive response against the fibrotic process.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!